<DOC>
	<DOCNO>NCT00502892</DOCNO>
	<brief_summary>Primary Objectives : - To determine maximum tolerate dose ( MTD ) Topotecan add fix dose regimen Ifosfamide Carboplatin child young adult solid tumor . - To evaluate toxicity associate administration Topotecan Ifosfamide Carboplatin ( TIC ) child young adult solid tumor . Secondary Objectives : - To evaluate duration neutropenia ( ANC &lt; 500/micro L ) thrombocytopenia ( PLT 50,000/ micro L 20,000/ micro L ) number day platelet transfusion course TIC chemotherapy use conjunction G-CSF NEUMEGA child young adult solid tumor . - To determine median number apheresis collection well CD34/kg , CD41/kg , CD61/kg CD34:41/kg CD34:61/kg per collection patient electively undergoing concurrent apheresis peripheral blood stem cell collection course 2 3 . - To determine median number peripheral blood mononuclear cell ( PBMC ) ex-vivo expand myeloid dendritic cell ( DC ) patient electively undergoing concurrent apheresis PBMC collection course 2 3 .</brief_summary>
	<brief_title>Topotecan , Ifosfamide Carboplatin Children Young Adults With Solid Tumors</brief_title>
	<detailed_description>All chemotherapy drug use study FDA approve commercially available drug design kill cancer cell . Before start treatment study , call `` screening test '' . These test help doctor decide eligible take part study . You physical exam routine blood ( 2 teaspoon ) urine test . You electrocardiogram ( ECG - test measure electrical activity heart ) . You chest x-ray scan ( CT , MRI , Bone , Ultrasound radionucleotide scan ) . You physician decide scan appropriate base disease clinical situation . You also bone marrow aspirate . To collect bone marrow aspirate , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . Women able child must negative pregnancy test start treatment . If find eligible take part study , assign specific dose topotecan . The first group participant receive small dose topotecan . If patient group able recover sufficient number platelet Day 22 severe side effect experience , next group participant treat large dose topotecan . The dose continue increase new group participant participant dose group unable recover sufficient number platelet Day 22 , severe side effect experience . There 3 patient group . The dos drug use study every participant . Topotecan , ifosfamide , carboplatin give first three day course . Ifosfamide carboplatin give vein one hour day along drug mesna . Mesna anti-cancer drug drug help protect bladder potential damaging effect ifosfamide . After first dose mesna , participant receive 3 dos ( one every three hour ) 15-30 minute . Topotecan give directly vein one-half hour begin one hour treatment ifosfamide , carboplatin , first dose mesna complete . Participants 22 year older receive Day 1 2 carboplatin . Starting fourth day course , give daily injection drug Filgrastim . Filgrastim growth factor naturally produce body stimulate production white blood cell ( infection fight cell ) . Filgrastim produce laboratory give patient higher dos body make . Filgrastim help body recover treatment . Filgrastim give injection skin day acceptable number white blood cell detect bloodstream . A second course chemotherapy begin soon 21 day start treatment long recover enough white blood cell platelet . If white blood cell platelet recover 21 day , begin next course recover . After first three course , re-evaluation disease . Re-evaluation require scan perform do study entry . If tumor show complete partial response treatment second course , continuation study discretion treat physician . If disease stable , mean change size degree tumor , treatment continue total 3 course overall . If disease get bad intolerable side effect occur , take study treatment option discuss . You may need hospitalize first three day chemotherapy course require visit outpatient time treatment receive laboratory follow-up evaluation . Participants may also require hospitalization side effect . During treatment , physical exam routine blood ( 2 teaspoon ) urine test . You also ECG , chest x-ray , scan think necessary . The physical exam do week Courses 1 - 3 . The blood test do Days 1 , 3 , 5 ; twice weekly Day 22 course . Urine test do Day 1 course end Course 2 . The scan ECG perform end course sooner suspected disease gotten bad . This investigational study . The drug study FDA approve commercially available . However , use together study experimental . Up 78 patient take part study . About 15 patient enrol UTMDACC .</detailed_description>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>1 . Age &lt; /= 45years . 2 . Histologic proof solid tumor malignancy ( exclude brain stem tumor ) initial diagnosis . Diagnostic Categories include : ) Sarcoma ( Soft Tissue Bone ) , b ) Kidney Tumors , c ) Brain Tumors , ) Neuroblastoma , e ) Hodgkin 's disease nonHodgkin 's lymphoma , f ) Other solid tumor ( gonadal germ cell tumor , malignant melanoma , retinoblastoma , liver tumor , miscellaneous tumor ) 3 . If previously treat , must radiographic , nuclear image , biopsy proof recurrence disease within 4 week prior study entry . 4 . Performance Level : Karnofsky &gt; /= 70 % patient &gt; 10 year age Lansky PlayPerformance Scale &gt; /=70 child &lt; /= 10 year age . Neurologic deficits patient CNS tumor must relatively stable minimum 2 week prior study entry . Patients unable walk paralysis , wheelchair consider ambulatory purpose assess performance score . 5 . Life Expectancy &gt; /= 8 week . 6 . Full recovery acute toxic effect prior chemo , immuno XRT : . No myelosuppressive chemotherapy &lt; /=2 week ( 4 week prior nitrosourea ) . b . At least 7 day since completion therapy biologic agent ( antineoplastic agent ) . c. No cranialspinal &amp; /or spinal ( &gt; 3600 cGy ) XRT . No XRT ( include TBI ) &gt; 50 % bone marrow space . d. No evidence active GVHD . For allogeneic Stem Cell Transplant ( SCT ) , &gt; /= 6 month must elapse . e. Has NOT receive exact combination &amp; dosage Topotecan , Carboplatin , &amp; Ifosfamide , study recommends , within last 3 month . 7 . Adequate Bone Marrow Function : ANC &gt; /=1000/ micro L ; Platelets &gt; /= 50,000/ micro L ( transfusion independent ) ; Hgb &gt; /= 8.0 gm/dL ( may receive RBC transfusion ) . 8 . Adequate Renal function : Serum creatinine &lt; /= 1.5 x normal age , Creatinine clearance radioisotope GFR &gt; /= low limit normal age . 9 . Adequate Liver function : Total bilirubin &lt; /=1.5 x normal age , SGPT ( ALT ) &lt; /= 5 x normal age albumin &gt; /=2 g/dL . 10 . Adequate Cardiac Function : Shortening fraction &gt; /= 27 % echocardiogram , Ejection fraction &gt; /= 50 % gate radionuclide study . 11 . Adequate Pulmonary Function : No evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; 94 % clinical indication determination . 12 . Central Nervous System Function : Patients seizure disorder may enrol anticonvulsant well control . CNS toxicity &lt; Grade 2 . 13 . Signed Informed Consent . 1 . Pregnancy Breast Feeding . 2 . Prior therapy particular topotecan , ifosfamide , carboplatin regimen last 3 month . 3 . Patients bone marrow solid tumor involvement . 4 . Patients receive cranialspinal spinal irradiation ( &gt; 3600 cGy ) . Patients receive radiation therapy ( include TBI ) great 50 % bone marrow space . 5 . Patients evidence active graft vs. host disease and/or patient wiht allogeneic Stem Cell Transplant [ SCT ] , &lt; 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Topotecan</keyword>
	<keyword>Hycamtin</keyword>
	<keyword>Ifosfamide</keyword>
	<keyword>Ifex</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Paraplatin</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Children</keyword>
	<keyword>Young Adults</keyword>
</DOC>